184 related articles for article (PubMed ID: 21082500)
1. Ovarian hyperstimulation syndrome: a preventable syndrome?
Rosenwaks Z; Benadiva C
Semin Reprod Med; 2010 Nov; 28(6):437-9. PubMed ID: 21082500
[No Abstract] [Full Text] [Related]
2. Physiology and pathology of ovarian hyperstimulation syndrome.
Gómez R; Soares SR; Busso C; Garcia-Velasco JA; Simón C; Pellicer A
Semin Reprod Med; 2010 Nov; 28(6):448-57. PubMed ID: 21082502
[TBL] [Abstract][Full Text] [Related]
3. Etiology of OHSS and use of dopamine agonists.
Soares SR
Fertil Steril; 2012 Mar; 97(3):517-22. PubMed ID: 22265002
[TBL] [Abstract][Full Text] [Related]
4. Middle cerebral artery thrombosis after IVF and ovarian hyperstimulation: a case report.
Jing Z; Yanping L
Fertil Steril; 2011 Jun; 95(7):2435.e13-5. PubMed ID: 21601668
[TBL] [Abstract][Full Text] [Related]
5. Prevention of ovarian hyperstimulation syndrome.
Wiwanitkit V
Fertil Steril; 2011 Jun; 95(8):e65; author reply e66. PubMed ID: 21530962
[No Abstract] [Full Text] [Related]
6. [Ovarian hyperstimulation syndrome].
Fukuda J; Shimizu Y; Tanaka T
Nihon Rinsho; 2006 Jun; Suppl 2():434-7. PubMed ID: 16817436
[No Abstract] [Full Text] [Related]
7. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome.
Spitzer D; Wogatzky J; Murtinger M; Zech MH; Haidbauer R; Zech NH
Fertil Steril; 2011 Jun; 95(8):2742-4.e1. PubMed ID: 21411081
[TBL] [Abstract][Full Text] [Related]
8. Etiology of ovarian hyperstimulation syndrome.
Orvieto R
Fertil Steril; 2012 Jun; 97(6):e27; author reply e28. PubMed ID: 22503413
[No Abstract] [Full Text] [Related]
9. Effect of the oral contraceptive pill on patients undergoing controlled ovarian hyperstimulation.
Frederick J; DaCosta V; Wynter S; Reid M; Frederick C; McKenzie C
West Indian Med J; 2004 Jan; 53(1):39-43. PubMed ID: 15114893
[TBL] [Abstract][Full Text] [Related]
10. Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee.
Tan BK; Mathur R
Hum Fertil (Camb); 2013 Sep; 16(3):151-9. PubMed ID: 23705784
[No Abstract] [Full Text] [Related]
11. Management of ovarian hyperstimulation syndrome guidelines. Produced on behalf of the BFS Policy and Practice Committee.
Tan BK; Mathur R;
Hum Fertil (Camb); 2013 Sep; 16(3):160-1. PubMed ID: 23705631
[No Abstract] [Full Text] [Related]
12. Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis.
Baumgarten M; Polanski L; Campbell B; Raine-Fenning N
Hum Fertil (Camb); 2013 Sep; 16(3):168-74. PubMed ID: 24047196
[TBL] [Abstract][Full Text] [Related]
13. Ovarian explosion following ovarian stimulation.
Taheripanah R; Taslimi S; Karimzadeh MA; Aflatoonian A; Zekavat H
Acta Obstet Gynecol Scand; 2011 Jul; 90(7):808. PubMed ID: 21488842
[No Abstract] [Full Text] [Related]
14. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
15. Can we eliminate severe ovarian hyperstimulation syndrome?
Orvieto R
Hum Reprod; 2005 Feb; 20(2):320-2. PubMed ID: 15567876
[TBL] [Abstract][Full Text] [Related]
16. Antral follicle count as a predictor of hyperresponse in controlled ovarian hyperstimulation/intrauterine insemination in unexplained sterility.
Checa MA; Prat M; Carreras R
Fertil Steril; 2010 Aug; 94(3):1105-7. PubMed ID: 20045519
[TBL] [Abstract][Full Text] [Related]
17. [Ovarian hyperstimulation syndrome--a risk of treatment for infertility].
Bangsbøll S
Nord Med; 1997 Sep; 112(7):236-9. PubMed ID: 9380489
[TBL] [Abstract][Full Text] [Related]
18. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose.
Kashyap S; Parker K; Cedars MI; Rosenwaks Z
Semin Reprod Med; 2010 Nov; 28(6):475-85. PubMed ID: 21082506
[TBL] [Abstract][Full Text] [Related]
19. Ovarian hyperstimulation syndrome associated with clomiphene citrate.
Mitchell SY; Fletcher HM; Williams E
West Indian Med J; 2001 Sep; 50(3):227-9. PubMed ID: 11769032
[TBL] [Abstract][Full Text] [Related]
20. [Use of cabergoline for prevention of ovarian hyperstimulation syndrome in assisted reproductive technologies].
Kozovski G; Angelova M; Kacarova P
Akush Ginekol (Sofiia); 2014; 53(5):34-5. PubMed ID: 25558669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
